The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Isoform-selective histone deacetylase inhibitors
Open accessAbstract
Histone deacetylase (HDAC) proteins are transcription regulators linked to cancer. As a result, multiple small molecule HDAC inhibitors are in various phases of clinical trials as anti-cancer drugs. The majority of HDAC inhibitors non-selectively influence the activities of eleven human HDAC isoforms, which are divided into distinct classes. This tutorial review focuses on the recent progress toward the identification of class-selective and isoform-selective HDAC inhibitors. The emerging trends suggest that subtle differences in the active sites of the HDAC isoforms can be exploited to dictate selectivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone deacetylases (HDACs) are epigenetic regulators that modulate gene expression by removing acetyl groups from lysine residues on proteins, affecting processes like cell proliferation, differentiation, and development.504,505”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [504]
Citations
Cites
Epigenetic programming by maternal behavior
Weaver, I. C. G., Cervoni, N., Champagne, F. A., D'Alessio, A. C., Sharma, S., Seckl, J. R., Dymov, S., Szyf, M., & Meaney, M. J. (2004) · Nature Neuroscience · doi:10.1038/nn1276 · Cited by 6,177
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
(2002) · PubMed · Cited by 732
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710
Research works printed but not linked: 1
- Furumai, 2002, Cancer Res., 62, 4916
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“504,505 Among them, HDAC6 has two catalytic domains and a C-terminal zinc fi nger domain, interacts with tau and α -tubulin, and is involved in the degradation of protein aggregates, mitochondrial transport, and cognitive memory, 506 – 509 making it relevant to AD pathology.”
BackgroundEpigenetic Modifications: Basic Mechanisms and Role in Cardiovascular Disease
Handy, D. E., Castro, R., & Loscalzo, J. (2011) · Circulation · doi:10.1161/circulationaha.110.956839 · Cited by 1,067
Short-chain fatty acids in diseases
Zhang, D., Jian, Y.-P., Zhang, Y.-N., Li, Y., Gu, L.-T., Sun, H.-H., Liu, M.-D., Zhou, H.-L., Wang, Y.-S., & Xu, Z.-X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01219-9 · Cited by 718
Bowers, E. M., Yan, G., Mukherjee, C., Orry, A., Wang, L., Holbert, M. A., Crump, N. T., Hazzalin, C. A., Liszczak, G., Yuan, H., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.03.006 · Cited by 666
Epigenetics: a molecular link between environmental factors and type 2 diabetes
Ling, C., & Groop, L. (2009) · Diabetes · doi:10.2337/db09-1003 · Cited by 617
“, HDAC inhibitors, can be used in the treatment of diabetic complications (13,111,112).”
BackgroundPROTACs: An Emerging Therapeutic Modality in Precision Medicine
Nalawansha, D. A., & Crews, C. M. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 490
Epigenetics in cancer: Targeting chromatin modifications
Ellis, L., Atadja, P. W., & Johnstone, R. W. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0860 · Cited by 479
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Tan, J., Cang, S., Ma, Y., Petrillo, R. L., & Liu, D. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-5 · Cited by 425
Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.3 · Cited by 404
Chen, X., Barozzi, I., Termanini, A., Prosperini, E., Recchiuti, A., Dalli, J., Mietton, F., Matteoli, G., Hiebert, S., & Natoli, G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121131109 · Cited by 397
“Although pan-HDACis are already available for therapy (15), the search for more specific compounds targeting subsets of HDACs or even single enzymes of the family is actively ongoing (52).”
BackgroundSanchez, H. N., Moroney, J. B., Gan, H., Shen, T., Im, J. L., Li, T., Taylor, J. R., Zan, H., & Casali, P. (2020) · Nature Communications · doi:10.1038/s41467-019-13603-6 · Cited by 361
VanderMolen, K. M., McCulloch, W., Pearce, C. J., & Oberlies, N. H. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.35 · Cited by 333
Liu, R., Wu, J., Guo, H., Yao, W., Li, S., Lu, Y., Jia, Y., Liang, X., Tang, J., & Zhang, H. (2023) · MedComm · doi:10.1002/mco2.292 · Cited by 264
Yuille, S., Reichardt, N., Panda, S., Dunbar, H., & Mulder, I. E. (2018) · PLOS ONE · doi:10.1371/journal.pone.0201073 · Cited by 257
Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides
Bressi, J. C., Jennings, A. J., Skene, R., Wu, Y., Melkus, R., Jong, R. D., O’Connell, S., Grimshaw, C. E., Navre, M., & Gangloff, A. R. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.091 · Cited by 261
Nutrition, Epigenetics, and Metabolic Syndrome
Wang, J., Wu, Z., Li, D., Li, N., Dindot, S. V., Satterfield, M. C., Bazer, F. W., & Wu, G. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4381 · Cited by 261
Role of HDACs in normal and malignant hematopoiesis
Wang, P., Wang, Z., & Liu, J. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1127-7 · Cited by 235
Epigenetics and cancer treatment
Kristensen, L. S., Nielsen, H. M., & Hansen, L. L. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.011 · Cited by 230
Isoform-specific histone deacetylase inhibitors: The next step?
Balasubramanian, S., Verner, E., & Buggy, J. J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.013 · Cited by 220
Pang, M., Kothapally, J., Mao, H., Tolbert, E., Ponnusamy, M., Chin, Y. E., & Zhuang, S. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00282.2009 · Cited by 211
Marcaurelle, L. A., Comer, E., Dandapani, S., Duvall, J. R., Gerard, B., Kesavan, S., Lee, M. D., Liu, H., Lowe, J. T., Marie, J.-C., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja105119r · Cited by 210
Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models
Cao, Y., Semanchik, N., Lee, S. H., Somlo, S., Barbano, P. E., Coifman, R., & Sun, Z. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911987106 · Cited by 200
Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses
Peng, K., Zheng, Y., Xia, W., & Mao, Z.-W. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00757f · Cited by 188
Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead
Mai, A., & Altucci, L. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.08.020 · Cited by 191
Marek, L., Hamacher, A., Hansen, F. K., Kuna, K., Gohlke, H., Kassack, M. U., & Kurz, T. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301254q · Cited by 177
HDAC inhibitors in parasitic diseases
Andrews, K. T., Haque, A., & Jones, M. K. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.97 · Cited by 161
Whitehead, L., Dobler, M. R., Radetich, B., Zhu, Y., Atadja, P. W., Claiborne, T., Grob, J. E., McRiner, A., Pancost, M. R., Patnaik, A., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.030 · Cited by 164
HDAC2: a critical factor in health and disease
Krämer, O. H. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.007 · Cited by 157
Ganai, S. A., Ramadoss, M., & Mahadevan, V. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666151021111609 · Cited by 170
Horne, W. S., Olsen, C. A., Beierle, J. M., Montero, A., & Ghadiri, M. R. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200805900 · Cited by 155
Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
Cappellacci, L., Perinelli, D. R., Maggi, F., Grifantini, M., & Petrelli, R. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181016163110 · Cited by 147
HDAC6 α-tubulin deacetylase: A potential therapeutic target in neurodegenerative diseases
Li, G., Jiang, H., Chang, M., Xie, H., & Hu, L. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.02.017 · Cited by 160
Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors
Kalin, J. H., & Bergman, J. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4001659 · Cited by 135
Targeting Histone Deacetylases in Diseases: Where Are We?
Benedetti, R., Conte, M., & Altucci, L. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5776 · Cited by 136
HDAC inhibitors and neurodegeneration: At the edge between protection and damage
Dietz, K. C., & Casaccia, P. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.011 · Cited by 138
Chromatin as an expansive canvas for chemical biology
Fierz, B., & Muir, T. W. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.938 · Cited by 133
Wagner, F. F., Olson, D. E., Gale, J. P., Kaya, T., Weïwer, M., Aidoud, N., Thomas, M., Davoine, E. L., Lemercier, B. C., Zhang, Y., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301355j · Cited by 129
Felice, C., Lewis, A., Armuzzi, A., Lindsay, J., & Silver, A. R. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13008 · Cited by 129
Yao, L., Mustafa, N. B., Tan, E. C., Poulsen, A., Singh, P., Duong‐Thi, M., Lee, J. X. T., Ramanujulu, P. M., Chng, W. J., Yen, J. J. Y., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00678 · Cited by 114
Genetic dissection of histone deacetylase requirement in tumor cells
Haberland, M., Johnson, A., Mokalled, M. H., Montgomery, R. L., & Olson, E. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903139106 · Cited by 112
HDAC inhibitors in experimental liver and kidney fibrosis
Beneden, K. V., Mannaerts, I., Pauwels, M., Branden, C. V. D., & van Grunsven, L. A. (2013) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-6-1 · Cited by 112
Wu, R., Lu, Z., Cao, Z., & Zhang, Y. (2011) · Journal of the American Chemical Society · doi:10.1021/ja111104p · Cited by 108
Glycemic memory associated epigenetic changes
Siebel, A. L., Fernández, A. Z., & El‐Osta, A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.06.005 · Cited by 102
Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity
Haggarty, S. J., & Tsai, L. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.04.009 · Cited by 111
Small Molecule Inhibitors of Zinc-dependent Histone Deacetylases
Wagner, F. F., Weïwer, M., Lewis, M. C., & Holson, E. B. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0226-1 · Cited by 107
Thaler, F., & Mercurio, C. (2013) · ChemMedChem · doi:10.1002/cmdc.201300413 · Cited by 107
Yang, E. G., Mustafa, N. B., Tan, E. C., Poulsen, A., Ramanujulu, P. M., Chng, W. J., Yen, J. J. Y., & Dymock, B. W. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00157 · Cited by 98
Discovery of histone deacetylase 8 selective inhibitors
Tang, W., Luo, T., Greenberg, E. F., Bradner, J. E., & Schreiber, S. L. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.134 · Cited by 98
Synthesis and Biological Evaluation of JAHAs: Ferrocene-Based Histone Deacetylase Inhibitors
Spencer, J., Amin, J., Wang, M., Packham, G., Alwi, S. S. S., Tizzard, G. J., Coles, S. J., Paranal, R. M., Bradner, J. E., & Heightman, T. D. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100295v · Cited by 97
Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide
Chang, J. J., Varghese, D., Gillam, M. C., Peyton, M., Modi, B. G., Schiltz, R. L., Girard, L., & Martínez, E. D. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.532 · Cited by 100
Discovery of the First Histone Deacetylase 6/8 Dual Inhibitors
Olson, D. E., Wagner, F. F., Kaya, T., Gale, J. P., Aidoud, N., Davoine, E. L., Lazzaro, F., Weïwer, M., Zhang, Y., & Holson, E. B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400390r · Cited by 98
Ligand Based Pharmacophore Modeling and Virtual Screening Studies to Design Novel HDAC2 Inhibitors
Kandakatla, N., & Ramakrishnan, G. (2014) · Advances in Bioinformatics · doi:10.1155/2014/812148 · Cited by 94
Synapse microarray identification of small molecules that enhance synaptogenesis
Shi, P., Skylar‐Scott, M. A., Ghosh, B., Wan, D., Wissner-Gross, Z. D., Mazitschek, R., Haggarty, S. J., & Yanik, M. F. (2011) · Nature Communications · doi:10.1038/ncomms1518 · Cited by 96
Macrocyclic Histone Deacetylase Inhibitors
Mwakwari, S. C., Patil, V., Guerrant, W., & Oyelere, A. K. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610792232079 · Cited by 96
Gurard‐Levin, Z. A., Kilian, K. A., Kim, J., Bähr, K., & Mrksich, M. (2010) · ACS Chemical Biology · doi:10.1021/cb100088g · Cited by 90
Thangapandian, S., John, S., Sakkiah, S., & Lee, K. W. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.06.024 · Cited by 87
Olsen, C. A., & Ghadiri, M. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900850t · Cited by 91
Montero, A., Beierle, J. M., Olsen, C. A., & Ghadiri, M. R. (2009) · Journal of the American Chemical Society · doi:10.1021/ja809508f · Cited by 94
Exploring the epigenetic drug discovery landscape
Prachayasittikul, V., Prathipati, P., Pratiwi, R., Phanus‐umporn, C., Malik, A. A., Schaduangrat, N., Seenprachawong, K., Wongchitrat, P., Supokawej, A., Prachayasittikul, V., et al. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1295954 · Cited by 84
Targeting FoxO transcription factors with HDAC inhibitors for the treatment of osteoarthritis
Ohzono, H., Hu, Y., Nagira, K., Kanaya, H., Okubo, N., Olmer, M., Gotoh, M., Kurakazu, I., Akasaki, Y., Kawata, M., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2021-221269 · Cited by 92
Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation.
Wong, M., Guo, C. H., & Zhang, J. (2014) · PubMed · Cited by 103
Histone Deacetylase Inhibitors as Therapeutic Agents for Acute Central Nervous System Injuries
Shein, N. A., & Shohami, E. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00038 · Cited by 85
Souto, J. A., Vaz, E., Lepore, I., Pöppler, A., Franci, G., Álvarez, R., Altucci, L., & de Lera, Á. R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100244y · Cited by 90
Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Mai, A., Rotili, D., Valente, S., & Kazantsev, A. G. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649349 · Cited by 80
Cancer therapy and vaccination
Aly, H. A. A. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.05.014 · Cited by 95
Huang, W., Chen, Y., Fedorov, A., Li, X., Jajamovich, G. H., Malyarenko, D. I., Aryal, M. P., LaViolette, P. S., Oborski, M. J., O’Sullivan, F., et al. (2019) · Tomography · doi:10.18383/j.tom.2018.00027 · Cited by 82
Chromatin-modifying agents in anti-cancer therapy
Seidel, C., Florean, C., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2012) · Biochimie · doi:10.1016/j.biochi.2012.05.012 · Cited by 85
Structural basis for the design and synthesis of selective HDAC inhibitors
Micco, S. D., Chini, M. G., Terracciano, S., Bruno, I., Riccio, R., & Bifulco, G. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.036 · Cited by 80
Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity
Quambusch, L., Landel, I., Depta, L., Weisner, J., Uhlenbrock, N., Müller, M. P., Glanemann, F., Althoff, K., Siveke, J. T., & Rauh, D. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201909857 · Cited by 77
Evolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer
Thompson, L., Jeusset, L. M., Lepage, C. C., & McManus, K. J. (2017) · Cancers · doi:10.3390/cancers9110151 · Cited by 80
Shetty, M. G., Pai, P., Deaver, R. E., Satyamoorthy, K., & Babitha, K. S. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105695 · Cited by 78
Histone deacetylase modulators provided by Mother Nature
Seidel, C., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2012) · Genes & Nutrition · doi:10.1007/s12263-012-0283-9 · Cited by 82
Histone Modification Therapy of Cancer
Biancotto, C., Frigè, G., & Minucci, S. (2010) · Advances in genetics · doi:10.1016/b978-0-12-380866-0.60013-7 · Cited by 83
Wanner, N., & Bechtel‐Walz, W. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2588-x · Cited by 66
Non-Peptide Macrocyclic Histone Deacetylase Inhibitors Derived from Tricyclic Ketolide Skeleton
Mwakwari, S. C., Guerrant, W., Patil, V., Khan, S. I., Tekwani, B. L., Gurard‐Levin, Z. A., Mrksich, M., & Oyelere, A. K. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100507q · Cited by 68
Wen, S., Packham, G., & Ganesan, A. (2008) · The Journal of Organic Chemistry · doi:10.1021/jo801866z · Cited by 75
Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity
Auzzas, L., Larsson, A., Matera, R., Baraldi, A., Deschênes-Simard, B., Giannini, G., Cabri, W., Battistuzzi, G., Gallo, G., Ciacci, A., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101092u · Cited by 71
HDAC inhibitors in kidney development and disease
Brilli, L. L., Swanhart, L. M., de Caestecker, M. P., & Hukriede, N. A. (2012) · Pediatric Nephrology · doi:10.1007/s00467-012-2320-8 · Cited by 66
Azetidinones as Zinc‐Binding Groups to Design Selective HDAC8 Inhibitors
Galletti, P., Quintavalla, A., Ventrici, C., Giannini, G., Cabri, W., Penco, S., Gallo, G., Vincenti, S., & Giacomini, D. (2009) · ChemMedChem · doi:10.1002/cmdc.200900309 · Cited by 63
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Luo, Y., & Li, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228828 · Cited by 62
Epigenetic mechanisms in mood disorders: Targeting neuroplasticity
Fass, D. M., Schroeder, F. A., Perlis, R. H., & Haggarty, S. J. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.01.041 · Cited by 69
Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands
Wood, T. E., Dalili, S., Simpson, C. D., Sukhai, M. A., Hurren, R., Anyiwe, K., Mao, X., Suárez, F., Gronda, M., Eberhard, Y., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0495 · Cited by 62
Lysine deacetylases and mitochondrial dynamics in neurodegeneration
Guedes-Dias, P., & Oliveira, J. M. A. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.005 · Cited by 64
Epigenetic profiling of the antitumor natural product psammaplin A and its analogues
García, J. L., Franci, G., Pereira, R., Benedetti, R., Nebbioso, A., Rodríguez‐Barrios, F., Gronemeyer, H., Altucci, L., & de Lera, Á. R. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.12.026 · Cited by 66
Pang, M., Ma, L., Liu, N., Ponnusamy, M., Zhao, T. C., Yan, H., & Zhuang, S. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23135 · Cited by 61
Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors
Tessier, P., Smil, D. V., Wahhab, A., Leit, S. M., Rahil, J. F., Li, Z., Déziel, R., & Besterman, J. M. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.010 · Cited by 65
Histone deacetylases (HDAC) in physiological and pathological bone remodelling
Cantley, M. D., Zannettino, A. C. W., Bartold, P. M., Fairlie, D. P., & Haynes, D. R. (2016) · Bone · doi:10.1016/j.bone.2016.11.028 · Cited by 65
Ebarasi, L., Oddsson, Á., Hultenby, K. R., Betsholtz, C., & Tryggvason, K. (2011) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3283477797 · Cited by 68
Liu, J., Yu, Y., Kelly, J., Sha, D., Alhassan, A.-B., Yu, W., Maletic, M. M., Duffy, J. L., Klein, D. J., Holloway, M. K., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00462 · Cited by 57
Indole-Derived Psammaplin A Analogues as Epigenetic Modulators with Multiple Inhibitory Activities
Pereira, R., Benedetti, R., Pérez-Rodríguez, S., Nebbioso, A., García‐Rodríguez, J., Carafa, V., Stuhldreier, M. C., Conte, M., Rodríguez‐Barrios, F., Stunnenberg, H. G., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300618u · Cited by 62
Histone Deacetylation Inhibitors as Modulators of Regulatory T Cells
von Knethen, A., Heinicke, U., Weigert, A., Zacharowski, K. D., & Brüne, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072356 · Cited by 60
HDAC inhibitors dysregulate neural stem cell activity in the postnatal mouse brain
Foti, S. B., Chou, A., Moll, A. D., & Roskams, A. J. (2013) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2013.03.008 · Cited by 64
Marson, C. M., Matthews, C. J., Yiannaki, E., Atkinson, S. J., Soden, P. E., Shukla, L., Lamadema, N., & Thomas, N. S. B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400634n · Cited by 56
Thomas, E. A. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8067-y · Cited by 55
Protein lysine acetylation in cellular function and its role in cancer manifestation
Arif, M., Senapati, P., Shandilya, J., & Kundu, T. K. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.10.002 · Cited by 61
Richardson, P. G. G., Mitsiades, C. S., Laubach, J. P., Hájek, R., Špıčka, I., Dimopoulos, M. A., Moreau, P., Siegel, D. S. D., Jagannath, S., & Anderson, K. C. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.03.006 · Cited by 58
Zinc-Containing Metalloenzymes: Inhibition by Metal-Based Anticancer Agents
Ye, R., Tan, C., Chen, B.-C., Li, R., & Mao, Z. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00402 · Cited by 57
Ganai, S. A. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.130 · Cited by 53
Giannini, G., Marzi, M., Marzo, M. D., Battistuzzi, G., Pezzi, R., Brunetti, T., Cabri, W., Vesci, L., & Pisano, C. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.101 · Cited by 53
Lu, D., Yan, J., Wang, L., Liu, H., Zeng, L., Zhang, M., Duan, W., Ji, Y., Cao, J., Geng, M., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00172 · Cited by 51
Metadata
- Authors
- Bieliauskas, A. V., & Pflum, M. K. H.
- Affiliations
- Wayne State University (US)
- Corresponding author
- Pflum, Mary Kay H.
- ORCID
- Pflum, Mary Kay H.
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2008
- Volume
- 37
- Issue
- 7
- Pages
- 1402
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- PMC
- PMC2593472
- OpenAlex
- W2124258829
- Cited by
- 350
- References
- 59
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 15 · 2023: 16 · 2022: 10 · 2021: 12 · 2020: 21 · 2019: 20 · 2018: 19 · 2017: 16 · 2016: 21 · 2015: 21 · 2014: 27 · 2013: 22 · 2012: 22
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Chemical Society Reviews (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of General Medical Sciences (GM 067657, R01GM067657)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- histone deacetylase inhibitors, HDAC isoforms, isoform selectivity, cancer therapy, small molecule inhibitors, transcriptional regulation
- MeSH terms
- Vorinostat, Antineoplastic Agents, Binding Sites, Enzyme Inhibitors, Histone Deacetylases, Humans, Hydroxamic Acids, Tumor Cells, Cultured, Drug Design, Protein Isoforms, Cell Proliferation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.